936901-75-6

Basic information

• Product Name: Cyclobutanol, 3-(8-aMino-1-broMoiMidazo[1,5-a]pyrazin-3-yl)-1-Methyl-, cis-
• Synonyms: Cyclobutanol, 3-(8-aMino-1-broMoiMidazo[1,5-a]pyrazin-3-yl)-1-Methyl-, cis-;(1s,3s)-3-(1-aMino-8-broMoH-pyrrolo[1,2-a]pyrazin-6-yl)-1-Methylcyclobutanol;3-(8-AMino-1-broMo-iMidazo[1,5-a]pyrazin-3-yl)-1-Methyl-cyclobutanol;(1S,3S)-3-(8-AMINO-1-BROMOIMIDAZO[1,5-A]PYRAZIN-3-YL)-1-METHYLCYCLOBUTANOL
• CAS NO: 936901-75-6
• Molecular Formula: C₁₁H₁₃BrN₄O
• Molecular Weight: 297.15112
• Mol File: 936901-75-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Cyclobutanol, 3-(8-aMino-1-broMoiMidazo[1,5-a]pyrazin-3-yl)-1-Methyl-, cis-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclobutanol, 3-(8-aMino-1-broMoiMidazo[1,5-a]pyrazin-3-yl)-1-Methyl-, cis-(936901-75-6)
• EPA Substance Registry System: Cyclobutanol, 3-(8-aMino-1-broMoiMidazo[1,5-a]pyrazin-3-yl)-1-Methyl-, cis-(936901-75-6)

Safety Data

• Hazardous Substances Data: 936901-75-6(Hazardous Substances Data)

Usage

General Description

Cyclobutanol, 3-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyl, cis- is a chemical compound that belongs to the class of cyclobutanols. It contains a cyclobutane ring with an attached 8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl and 1-methyl group in a cis configuration. Cyclobutanol, 3-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyl-, cis- may have potential applications in pharmaceutical research and development due to its structural features and potential biological activities. The specific chemical properties and uses of this compound would depend on further research studies and investigations.

Upstream product

• 936901-74-5 cis-3-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol 
• 936901-73-4 3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone 

Downstream Products

• 867160-71-2 linsitinib 
• 1356958-77-4 cis-8-amino-3-(3-hydroxy-3-methyl-cyclobutyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-7-ium chloride 
• 1356958-93-4 cis-8-amino-3-(3-hydroxy-3-methyl-cyclobutyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-7-ium methanesulfonate 
• 1196388-86-9 C₂₄H₂₄N₄O₃ 

Relevant articles and documents

Discovery of potent, selective and orally bioavailable imidazo[1,5-a] pyrazine derived ACK1 inhibitors

This Letter describes the medicinal chemistry effort towards a series of novel imidazo[1,5-a]pyrazine derived inhibitors of ACK1. Virtual screening led to the discovery of the initial hit, and subsequent exploration of structure-activity relationships and

Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA?).